Introduction: Polypoidal choroidal vasculopathy (PCV) is a choroidal pathology characterized by frequent occurrences of subretinal hemorrhages and resistance to monotherapies such as ranibizumab or bevacizumab intravitreal injections (IVT). The purpose of this study is to evaluate both the anatomical and functional efficacy of aflibercept IVT as a monotherapy in PCV in a Caucasian population. Methods: We conducted a prospective multicenter study in either treatment-naïve patients with PCV or PVC patients who had not been treated with anti-VEGF within the previous 3 months or with photodynamic therapy (PDT) within the previous 6 months. All patients had been treated with 3 initial monthly loading doses of aflibercept followed by a Q8 regimen for 28 weeks in total. All patients underwent a complete ophthalmic examination including the measurement of best-corrected visual acuity (BCVA) before each IVT and after 28 weeks as well as an optical coherent tomography (OCT) of the macula. At baseline and 28 weeks, the polypoidal dilations were analyzed with indocyanine green angiography. Results: Thirty-four eyes of 34 patients were included in this study. All patients were followed for 28 weeks and received 5 aflibercept IVT. The mean baseline BCVA was 55 letters. After 28 weeks, significant +13 letters in BCVA and a regression of exudative signs on OCT in all patients were observed. In 62% of the cases, polyp disappearance was observed on indocyanine green angiography. Discussion: In this study on a Caucasian population, we showed that aflibercept as a monotherapy provided both a significant visual gain and the regression of polypoidal dilations. Aflibercept use in monotherapy may contribute to reduce the hemorrhagic risk and atrophy linked to PDT.

Keywords:
Polypoidal choroidal vasculopathy, Aflibercept, Optical coherent tomography, Indocyanine green angiography, Prospective study, Caucasian population
1.
Yannuzzi LA, Sorenson J, Spaide RF, Lipson B: Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990; 10: 1–8.
2.
Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, Wang JJ, et al: The prevalence of age related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2010; 117: 921–927.
3.
Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY: Age-related macular degeneration. Lancet 2012; 379: 1728–1738.
4.
Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA: The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol 1997; 115: 478–485.
5.
Coscas G, Lupidi M, Coscas F, Benjelloun F, Zerbib J, Dirani A, et al: Toward a specific classification of polypoidal choroidal vasculopathy: idiopathic disease or subtype of age-related macular degeneration. Invest Ophthalmol Vis Sci 2015; 56: 3187–3195.
6.
Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA: Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 2010; 55: 501–515.
7.
Nakai S, Honda S, Miki A, Matsumiya W, Nakamura M: Comparison of the 12-month outcomes of intravitreal ranibizumab between two angiographic subtypes of polypoidal choroidal vasculopathy. Ophthalmologica 2017; 237: 123–127.
8.
Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J, Sorenson J, et al: Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 2002; 22: 529–535.
9.
Tomita K, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Otani A, et al: Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol 2012; 153: 68–80.
10.
Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, et al: Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol 2013; 156: 644–651.
11.
Koh AH, Expert PCV Panel, Chen L-J, Chen SJ, Chen Y, Giridhar A, et al: Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina 2013; 33: 686–716.
12.
Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al: EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012; 32: 1453–1464.
13.
Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al: EVEREST II study: Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol 2017; 135: 1206–1213.
14.
Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M, et al: Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2007; 27: 335–341.
15.
Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99: 11393–11398.
16.
Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong V, Nguyen QD, et al: Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014; 121: 193–201.
17.
Lee JE, Shin JP, Kim HW, Chang W Kim YC, Lee SJ, et al: VAULT study group. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study. Graefes Arch Clin Exp Ophthalmol 2017; 255: 493–502.
18.
Oshima Y, Kimoto K, Yoshida N, Fujisawa K, Sonoda S, Kubota T, et al: One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: THE APOLLO Study. Ophthalmologica 2017; 238: 163–171.
19.
Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, et al: One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2017; 255: 541–548.
20.
Jeong S, Sagong M: Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy. Br J Ophthalmol 2017; 101: 758–763.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.